ABHIJIT PAWAR, ADAR POONAWALA PARTNER WITH PUNE-BASED MYLAB TO SCALE-UP PRODUCTION OF CORONAVIRUS TEST KITS
Pune’s Mylab is the first Indian company to get commercial approval for COVID-19 test kits in India with 100 per cent concordance results. Mylabs has partnered with Serum Institute of India’s CEO Adar Poonawalla and Abhijit Pawar to scale-up production of the test kits.
Pune: In order to scale up the operations and escalate faster delivery of testing kits for the novel coronavirus (COVID-19), Pune-based molecular diagnostics company Mylab Discovery Solutions Pvt Ltd has partnered with Serum India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG. Funds invested will be used for scaling production of COVID-19 testing kits and expansion of molecular diagnostic solutions.
“We are honoured to stand by our Prime Minister and our government while supporting them during these trying times. This partnership will ensure we do our bit to help in this time of crisis.“ said Abhijit Pawar, Chairman AP Globale and MD - Sakal Media Group.
Talking about the partnership, Serum Institute of India’s CEO Adar Poonawalla said, “In the next few weeks we will be ramping up the production of the COVID-19 testing kits taking from 1.5 lakh units/week to 20 lakh units/week. The shortage of testing kits will come to an end in a month or two”.
“This partnership can impact billions across the world, especially India”, said Hasmukh Rawal, MD, Mylab Discovery Solutions.
Mylab is the first Indian company to get commercial approval for its testing kits named as Mylab PathoDetect COVID-19 Qualitative PCR kit. The testing kit is approved by Indian FDA/ Central Drugs Standard Control Organisation (CDSCO) and ICMR evaluation. “This will help Mylabs create a world-class organisation, which will help India become a leader in molecular diagnostics’’, noted Sujit Jain, Director, Mylab Discovery solutions Pvt ltd, MD Netsurf.
“Global innovation is the need of the hour to curb this pandemic that has affected millions across the world. The need for the maintenance and manufacturing of medical and healthcare equipment at the pace required to keep the numbers at bay has never been more important. Mylabs and their team have shown exceptionally innovative capabilities when they were able to develop a time-saving testing kit within six-weeks of its outbreak.
“Keeping in mind their resilient approach and quick response, I am certain that the company has a variety of similar innovation-driven projects which will help bring drastic improvements in the healthcare sector. The investment towards Mylab will enable them to build their infrastructure and expand their capabilities further”, Mr Poonawalla further added.
The Mylab manufacturing facility, approved by FDA/CDSCO is compliant with MDR 2017 regulation for Manufacturing Medical Device of Class A,B,C and D and ISO 13485: 2016 certification. The legal advisory for this partnership was led by Hitesh Jain, Managing Partner, Parinam Law Associates.
About Mylab Discovery Solutions
Mylab Discovery Solutions Pvt. Ltd. is an Indian biotechnology company with a focus on advanced In-Vitro Diagnostics. The company offers a wide spectrum of molecular diagnostics solutions, developed in-house by its R&D team in Pune, which helped it become the first Indian company to get commercial approval for COVID-19 test kits in India, with 100% concordance results.
In 2019, Mylab became India's first FDA (CDSCO) approved manufacturer for RT-PCR based molecular diagnostic kits for detection and quantification of HIV, HBV and HCV. This was followed by NatSpertTM, Individual Donor Nucleic Acid Amplification Test (ID-NAT) screening kits for blood banks and hospitals, thereby becoming the first company in Asia and 2nd company worldwide to manufacture ID-NAT kits approved by regulatory bodies.
Mylab aims to simplify disease detection and to make it affordable with state-of-the-art technology. It is also working on a sample-to-result machine to automate IVD processes. Mylab is a homegrown R&D company from India with a vision to contribute to clinical diagnostics, pharmaceutical drug discovery, biomedical research, Agri genomics and animal and food safety at a global level.
About Adar Poonawalla, CEO, Serum Institute of India (SII)
Adar Poonawalla is the Chief Executive Officer (CEO) and the Executive Director of Serum Institute of India. Apart from being among the leading businessmen in India, Mr Poonawalla has helmed the cause of global immunisation cover and endeavours towards achieving 100% cover for denizens.
Setting an example among the top CEO’s in India Adar has championed various causes including – Adar Poonawalla Clean City Initiative and Adar Poonawalla Maharashtra Tennis Academy. Additionally, in 2011, he founded the Villoo Poonawalla Foundation, focussing on Healthcare, Education, Water, Sanitation and the Environment.
About AP Globale (APG)
AP Globale, a positive Impact Business Solutions company, with interests in diverse businesses, including Sakal Media, will be helping Mylabs, scale its operations within India and globally. Abhijit Pawar, Chairman of APG, will be joining the board of the company.
For Media queries:
Please contact Saurabh / Deepak at firstname.lastname@example.org or at +91-9999-03-9948